BioPharmSignal logoBioPharmSignal

Biotech News

Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer

Corcept (CORT)CorceptClinical readout

Data demonstrate a 35 percent reduction in risk of death Lifyorli, in combination with nab-paclitaxel, added to NCCN Guidelines ® as a preferred regimen Lifyorli approved by the FDA in March 2026 REDWOOD CITY, Calif. --(BUSINESS WIRE)--Apr. 10, 2026-- Corcept Therapeutics Incorporated (NASDAQ:

Related news

CORTCorcept2026-04-21 17:09 EST

Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026

CORTCorcept2026-04-30 20:05 EST

Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis

VKTXViking Therapeutics2026-05-12 11:05 EST

Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026

NBIXNeurocrine Biosciences2026-08-12 12:30 EST

Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia

NBIXNeurocrine Biosciences2026-07-01 20:05 EST

Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia

CRNXCrinetics Pharmaceuticals2026-06-14 20:30 EST

Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026

VKTXViking Therapeutics2026-03-26 11:05 EST

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735

CRNXCrinetics Pharmaceuticals2026-01-05 13:00 EST

Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia

View all latest news

Corcept

Cortisol Modulation Platform Corcept Therapeutics develops medicines that selectively modulate the glucocorticoid receptor and the effects of cortisol. Its portfolio spans endocrinology, oncology, metabolism and neurology. Cushing’s Syndrome Franchise Corcept has an established commercial business treating hypercortisolism in patients...

Recent company news

CORTCorcept2026-07-29 20:05 EST

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

CORTCorcept2026-07-22 20:05 EST

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

CORTCorcept2026-06-17 20:28 EST

Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome

CORTCorcept2026-06-06 20:45 EST

Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®

CORTCorcept2026-05-29 20:33 EST

Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure

Stock data

Close
122.25 USD
Market cap
7.64B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States